COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action

Dermatol Ther. 2020 Jul;33(4):e13298. doi: 10.1111/dth.13298. Epub 2020 Mar 22.

Authors

Claudio Conforti¹, Roberta Giuffrida², Caterina Dianzani³, Nicola Di Meo¹, Iris Zalaudek¹

Affiliations

¹ Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
² Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, Italy.
³ Department of Plastic, Reconstructive and Cosmetic Surgery, Dermatology Section, Campus Bio-Medico University Hospital, Rome, Italy.

No abstract available

Publication types

Letter

MeSH terms

COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / epidemiology
Humans
Immunosuppressive Agents / administration & dosage*
Immunosuppressive Agents / adverse effects
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / epidemiology
Psoriasis / complications
Psoriasis / drug therapy*
Risk Factors

Substances

Immunosuppressive Agents